317 related articles for article (PubMed ID: 29779045)
1. Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia.
Walker Z; Gandolfo F; Orini S; Garibotto V; Agosta F; Arbizu J; Bouwman F; Drzezga A; Nestor P; Boccardi M; Altomare D; Festari C; Nobili F;
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1534-1545. PubMed ID: 29779045
[TBL] [Abstract][Full Text] [Related]
2. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain
Nobili F; Arbizu J; Bouwman F; Drzezga A; Agosta F; Nestor P; Walker Z; Boccardi M;
Eur J Neurol; 2018 Oct; 25(10):1201-1217. PubMed ID: 29932266
[TBL] [Abstract][Full Text] [Related]
3. The utility of FDG-PET in the differential diagnosis of Parkinsonism.
Brajkovic L; Kostic V; Sobic-Saranovic D; Stefanova E; Jecmenica-Lukic M; Jesic A; Stojiljkovic M; Odalovic S; Gallivanone F; Castiglioni I; Radovic B; Trajkovic G; Artiko V
Neurol Res; 2017 Aug; 39(8):675-684. PubMed ID: 28378615
[TBL] [Abstract][Full Text] [Related]
4.
Meyer PT; Frings L; Rücker G; Hellwig S
J Nucl Med; 2017 Dec; 58(12):1888-1898. PubMed ID: 28912150
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG PET Is an Early Predictor of Overall Survival in Suspected Atypical Parkinsonism.
Hellwig S; Frings L; Amtage F; Buchert R; Spehl TS; Rijntjes M; Tüscher O; Weiller C; Weber WA; Vach W; Meyer PT
J Nucl Med; 2015 Oct; 56(10):1541-6. PubMed ID: 26229141
[TBL] [Abstract][Full Text] [Related]
6. [¹⁸F]FDG-PET is superior to [¹²³I]IBZM-SPECT for the differential diagnosis of parkinsonism.
Hellwig S; Amtage F; Kreft A; Buchert R; Winz OH; Vach W; Spehl TS; Rijntjes M; Hellwig B; Weiller C; Winkler C; Weber WA; Tüscher O; Meyer PT
Neurology; 2012 Sep; 79(13):1314-22. PubMed ID: 22914831
[TBL] [Abstract][Full Text] [Related]
7. Transcranial sonography and [18F]fluorodeoxyglucose positron emission tomography for the differential diagnosis of parkinsonism: a head-to-head comparison.
Hellwig S; Reinhard M; Amtage F; Guschlbauer B; Buchert R; Tüscher O; Weiller C; Niesen WD; Meyer PT
Eur J Neurol; 2014 Jun; 21(6):860-6. PubMed ID: 24602186
[TBL] [Abstract][Full Text] [Related]
8. FDG PET in the differential diagnosis of parkinsonian disorders.
Eckert T; Barnes A; Dhawan V; Frucht S; Gordon MF; Feigin AS; Eidelberg D
Neuroimage; 2005 Jul; 26(3):912-21. PubMed ID: 15955501
[TBL] [Abstract][Full Text] [Related]
9. Recent Advancement and Clinical Implications of 18FDG-PET in Parkinson's Disease, Atypical Parkinsonisms, and Other Movement Disorders.
Peralta C; Biafore F; Depetris TS; Bastianello M
Curr Neurol Neurosci Rep; 2019 Jun; 19(8):56. PubMed ID: 31256288
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET study on the idiopathic Parkinson's disease from several parkinsonian-plus syndromes.
Zhao P; Zhang B; Gao S
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S60-2. PubMed ID: 22166456
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia.
Nestor PJ; Altomare D; Festari C; Drzezga A; Rivolta J; Walker Z; Bouwman F; Orini S; Law I; Agosta F; Arbizu J; Boccardi M; Nobili F; Frisoni GB;
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1509-1525. PubMed ID: 29736698
[TBL] [Abstract][Full Text] [Related]
12. The value of putaminal diffusion imaging versus 18-fluorodeoxyglucose positron emission tomography for the differential diagnosis of the Parkinson variant of multiple system atrophy.
Baudrexel S; Seifried C; Penndorf B; Klein JC; Middendorp M; Steinmetz H; Grünwald F; Hilker R
Mov Disord; 2014 Mar; 29(3):380-7. PubMed ID: 24243813
[TBL] [Abstract][Full Text] [Related]
13. Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography.
Tripathi M; Dhawan V; Peng S; Kushwaha S; Batla A; Jaimini A; D'Souza MM; Sharma R; Saw S; Mondal A
Neuroradiology; 2013 Mar; 55(4):483-92. PubMed ID: 23314836
[TBL] [Abstract][Full Text] [Related]
14. Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia.
Boccardi M; Festari C; Altomare D; Gandolfo F; Orini S; Nobili F; Frisoni GB;
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1470-1486. PubMed ID: 29713763
[TBL] [Abstract][Full Text] [Related]
15. [
El Ouartassi A; Giordana C; Schiazza A; Chardin D; Darcourt J
Brain Imaging Behav; 2023 Dec; 17(6):619-627. PubMed ID: 37474673
[TBL] [Abstract][Full Text] [Related]
16. Accuracy of MR markers for differentiating Progressive Supranuclear Palsy from Parkinson's disease.
Zanigni S; Calandra-Buonaura G; Manners DN; Testa C; Gibertoni D; Evangelisti S; Sambati L; Guarino M; De Massis P; Gramegna LL; Bianchini C; Rucci P; Cortelli P; Lodi R; Tonon C
Neuroimage Clin; 2016; 11():736-742. PubMed ID: 27330973
[TBL] [Abstract][Full Text] [Related]
17. Brain 18F-FDG PET imaging in the differential diagnosis of parkinsonism.
Akdemir ÜÖ; Tokçaer AB; Karakuş A; Kapucu LÖ
Clin Nucl Med; 2014 Mar; 39(3):e220-6. PubMed ID: 24321825
[TBL] [Abstract][Full Text] [Related]
18. IBZM SPECT and FDG PET in the differential diagnosis of Parkinsonian syndromes: comparison with respect to inter-rater agreement.
Derlin T; Afzal W; Wilke F; Apostolova I; Klutmann S; Meyer PT; Buhmann C; Hesse S; Buchert R
Nuklearmedizin; 2010; 49(4):139-47. PubMed ID: 20502846
[TBL] [Abstract][Full Text] [Related]
19. The utility of susceptibility-weighted imaging for differentiating Parkinsonism-predominant multiple system atrophy from Parkinson's disease: correlation with 18F-flurodeoxyglucose positron-emission tomography.
Yoon RG; Kim SJ; Kim HS; Choi CG; Kim JS; Oh J; Chung SJ; Lee CS
Neurosci Lett; 2015 Jan; 584():296-301. PubMed ID: 25450142
[TBL] [Abstract][Full Text] [Related]
20. New advances in tau imaging in parkinsonism.
Valli M; Strafella AP
Int Rev Psychiatry; 2017 Dec; 29(6):628-635. PubMed ID: 29206491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
